⚡Cipla’s COVID-19 Drug Cipremi Set to Cost Less Than Rs 5,000 per Vial
By IANS
The Drug Controller General of India (DCGI) has granted Cipla regulatory approval for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.